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Abstract
The functional consequences of missense variants in disease genes are difficult to predict. We assessed if gene expression
profiles could distinguish between BRCA1 or BRCA2 pathogenic truncating and missense mutation carriers and familial
breast cancer cases whose disease was not attributable to BRCA1 or BRCA2 mutations (BRCAX cases). 72 cell lines from
affected women in high-risk breast ovarian families were assayed after exposure to ionising irradiation, including 23 BRCA1
carriers, 22 BRCA2 carriers, and 27 BRCAX individuals. A subset of 10 BRCAX individuals carried rare BRCA1/2 sequence
variants considered to be of low clinical significance (LCS). BRCA1 and BRCA2 mutation carriers had similar expression
profiles, with some subclustering of missense mutation carriers. The majority of BRCAX individuals formed a distinct cluster,
but BRCAX individuals with LCS variants had expression profiles similar to BRCA1/2 mutation carriers. Gaussian Process
Classifier predicted BRCA1, BRCA2 and BRCAX status, with a maximum of 62% accuracy, and prediction accuracy decreased
with inclusion of BRCAX samples carrying an LCS variant, and inclusion of pathogenic missense carriers. Similarly, prediction
of mutation status with gene lists derived using Support Vector Machines was good for BRCAX samples without an LCS
variant (82–94%), poor for BRCAX with an LCS (40–50%), and improved for pathogenic BRCA1/2 mutation carriers when the
gene list used for prediction was appropriate to mutation effect being tested (71–100%). This study indicates that mutation
effect, and presence of rare variants possibly associated with a low risk of cancer, must be considered in the development of
array-based assays of variant pathogenicity.
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Introduction
Approximately 7% of breast cancer cases occur in women with a
strong family history of the disease [1]. Mutations in BRCA1 and
BRCA2 account for a considerable proportion of these familial breast
cancer cases, with the average cumulative risk in BRCA1 and BRCA2
mutation carriers by age 70 years estimated at 65% and 45%,
respectively [2]. The Breast Cancer Information Core (BIC)
database (http://research.nhgri.nih.gov/bic/) currently has more
than 1400 and 1800 unique sequence variants listed in the BRCA1
and BRCA2 genes, respectively. These include frameshift, nonsense,
missense, splice site alterations and polymorphisms. Greater than a
third of the BRCA1 and greater than half of the BRCA2 unique
variants are ‘‘unclassified variants’’ without compelling evidence of
pathogenicity or functional significance. The majority of unclassified
variants recorded in the BIC database are predicted missense
changes (more than 400 BRCA1 and 800 BRCA2). However other
variants which may be categorised as unclassified variants are in-
frame deletions or duplications, variants that may disrupt splicing, or
variants in the 39UTR that may affect RNA stability (www.kconfab.
org). BRCA1/2 unclassified variants represent a problem in the
clinical setting as it is not known which variants are associated with
the high risk of disease reported for classical truncating mutations.
Several functional assays may be used to determine the
significance of unclassified variants, including transcription
activation and complementation assays [3–9], but a disadvantage
of biochemical assays is that they rely on the functions of specific
domains of the protein, require specialized laboratory skills, and
are time–consuming to perform. Other methods for classifying
variants include the analysis of clinical and histopathological data
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to predict the effect of the amino acid change on structure and
multiple sequence alignment strategies [12]; [13–15]. Integrated
evaluation of unclassified variants which combines several
approaches, such as the analysis of co-segregation of the mutation
with disease, co-occurrence of the variant with a deleterious
mutation, sequence conservation of the amino acid change,
severity of amino acid change, tumor loss of heterozygosity, and
tumor histopathology classification, provides a quantitative tool for
the classification of variants [16–22]. This multifactorial method
was developed to classify such rare unclassified variants into two
categories, variants with features of classical high-risk mutations
(termed pathogenic), and variants that do not have the features of
a high-risk mutation (termed neutral or low clinical significance
(LCS)). While the availability of appropriate biospecimens (e.g.
number of families and tumors) for inclusion in likelihood
prediction is a major factor determining the classification of any
single variant, another major caveat of the multifactorial approach
is that it is not appropriate for the evaluation of possible moderate
or low risk variants, since it uses high-risk mutations as reference
for the underlying assumptions [16,19,20]. Therefore, the current
multifactorial method cannot exclude the possibility that rare
variants classified to be of low clinical significance may be
associated with a moderate or low risk of cancer.
Gene expression profiling has increased our understanding of
the molecular events in breast tumor development, has been used
to predict prognosis, and has characterised breast tumors into
subtypes [23–27]. The value of expression profiling for identifying
underlying high-risk gene mutation status is indicated by a number
of studies. A distinct gene expression profile has been reported for
breast tumors of BRCA1 mutation carriers [23,28,29], expected to
be homozygous for loss of BRCA1 function at the somatic level. In
addition, the existence of distinct gene expression profiles for
heterozygous loss of BRCA1 and BRCA2 function is supported by
accurate separation of short-term cultures of fibroblasts carrying a
germline mutation in the BRCA1 or BRCA2 genes, compared to
healthy women undergoing reduction mammoplastic surgery with
no family or personal history of any cancer or sporadic breast-
cancer-affected controls [30,31]. Lymphoblastoid cell lines (LCLs)
have also been shown to have distinct mRNA expression
phenotypes for heterozygous carriers of ATM mutations, some of
which are known to be associated with an increased risk in breast
cancer [32,33]. These findings suggest that germline gene
expression signatures, including those from fibroblasts or LCLs,
may be used to define BRCA1 or BRCA2 mutation status and to
assist in assessing the clinical significance of BRCA1 and BRCA2
unclassified variants.
In this study we compared LCL gene expression signatures of
breast cancer cases carrying pathogenic mutations in BRCA1 or
BRCA2, to familial breast cancer cases with no known BRCA1/2
mutations (BRCAX). We also considered the possibility that
BRCAX individuals with a BRCA1 or BRCA2 sequence variant
classified to be neutral/low clinical significance (LCS) using
multifactorial likelihood analysis may differ in gene expression
profile from BRCAX individuals without such sequence variants. In
addition, since truncating alterations comprise the majority of
known pathogenic mutations but most BRCA1 and BRCA2
unclassified variants are predicted missense alterations, we
compared profiles from individuals with known missense or
truncating mutations to determine if mutation effect will affect the
mutation-associated expression profile for each gene. We derived
gene lists to predict mutation status defined by gene and mutation
effect, and then tested the efficacy of these gene lists to predict the
gene mutation status of LCLs. We provide evidence that gene lists
differ according to gene and mutation effect, and according to the
presence of sequence variants of low clinical significance. We also
demonstrate that the use of appropriately-derived gene lists
improves the prediction of pathogenicity of known mutations.
Results
Differences in LCL Post-Irradiation Gene Expression
between BRCAX Individuals with or without a Sequence
Variant of Low Clinical Significance
The ultimate aim of this experiment was to establish if gene
expression profiles could distinguish between BRCA1 or BRCA2
pathogenic mutation carriers and familial breast cancer cases
whose disease was not attributable to BRCA1 or BRCA2 mutations
(BRCAX cases). BRCAX breast cancer families are likely to result
from mutations in several other genes, and thus represent a
heterogeneous group. Moreover, included in the BRCAX group
were a subset of 10 BRCAX individuals who carried a BRCA1/2
variant previously classified to be of low clinical significance using
multifactorial likelihood approaches [8,19,21,22]. Unsupervised
hierarchical clustering showed that BRCAX LCLs containing a
BRCA1 or BRCA2 variant of low clinical significance clustered
away from the majority of remaining BRCAX samples (Figure 1). A
t-test with Benjamini and Hochberg multiple testing correction
[34] was performed to determine if there were gene expression
differences between the BRCAX individuals with an LCS variant
and those without an LCS variant. Expression of 631 genes
differed between the two BRCAX subgroups (5% of the 631 genes
identified would be expected to pass this restriction by chance). For
this reason, BRCAX samples were stratified according to the
presence of an LCS variant for further analyses.
Gene expression is similar for carriers of BRCA1 and BRCA2
truncating mutations and rare sequence variants of low clinical
significance, but differs from BRCA1 and BRCA2 missense
mutations and BRCAX non-BRCA1/2 familial cases.
Unsupervised hierarchical clustering (Figure 2) of LCL
expression data from all samples revealed that BRCA1 and BRCA2
Author Summary
Inherited mutations in the genes BRCA1 and BRCA2
increase risk of breast cancer and contribute to a
proportion of breast cancer families. However, more than
half of the reported sequence alterations in BRCA1 and
BRCA2 are currently of unknown clinical significance. We
analysed gene expression in lymphoblastoid cell lines
derived from blood of patients with sequence alterations
in BRCA1 and BRCA2 and compared these to lymphoblas-
toid cells from familial breast cancer patients without such
alterations. We then classified these lymphoblastoid cells
based on their gene profiles. We found that BRCA1 and
BRCA2 samples were more similar to each other than to
familial breast cancer patients without BRCA1/2 mutations,
and that the type of sequence change in BRCA1 and BRCA2
(missense or truncating) influenced gene expression. We
included in the study ten familial breast cancer samples,
which carried sequence changes in BRCA1 or BRCA2, that
are believed to be of little clinical significance. Interestingly
these samples were distinct from other familial breast
cancer cases without any sequence alteration in BRCA1 or
BRCA2, indicating that further work needs to be performed
to determine the possible association of these ‘‘low clinical
significance’’ sequence changes with a low to moderate
risk of cancer.
Expression Profiles of BRCA1/2 Variants
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without an LCS variant. This result suggests that germline effects
of heterozygous mutations in BRCA1 and BRCA2 cannot easily be
separated using the experimental conditions used in this study.
Although BRCAX samples tended to cluster distinctly from
BRCA1/2 samples, nine of ten BRCAX individuals who carried a
BRCA1/2 variant previously classified to be of low clinical
significance fell within the major BRCA1 or BRCA2 mutation
cluster. In contrast, six of the nine pathogenic missense mutations
of BRCA1 or BRCA2 fell into a BRCA1/2 outlier group, which
clustered closer to the BRCAX samples.
Gaussian Process Classifier Prediction of BRCA1, BRCA2
and BRCAX Mutation Status
To determine the accuracy of using gene expression data from
LCLs to predict BRCA1/2 pathogenic carriers and BRCAX
individuals, we used a Gaussian Process Classifier (GPC). GPC
analysis was used previously in an analysis of microarray profiles
from irradiated short-term fibroblasts of BRCA1/2 mutation
carriers [31], and allows for multiway comparison of groups. For
GPC analysis 2031 genes which were significantly over/under-
expressed at the 5% significance level were selected. The GPC was
used in a three way comparison to compare BRCA1 truncating
mutation carriers to BRCA2 truncating mutation carriers, and to
BRCAX samples without an LCS variant. Samples with BRCA1 or
BRCA2 pathogenic missense mutations or classified as BRCAX with
an LCS variant were then included to determine their affect on the
prediction accuracy. A summary of the prediction accuracy is
shown in Table 1. The highest prediction accuracy (62.26%) was
achieved when the analysis excluded samples classified as BRCAX
with an LCS, and samples with BRCA1 or BRCA2 missense
mutations. This prediction accuracy is above the expected
performance, as a random prediction with three classes comprised
of a similar sample number would be 33% accuracy. When
BRCA1 and BRCA2 samples were compared to only BRCAX
samples with an LCS variant, the prediction dropped to 43.46%,
and the addition of the BRCAX samples without an LCS variant
improved the accuracy. In all comparisons the inclusion of the
pathogenic non-truncating mutations of BRCA1 and BRCA2
lowered the prediction accuracy.
Comparison of Gene Expression Profiles between BRCAX
and BRCA1 or BRCA2 LCLs
In the clinical setting, unclassified sequence variants of BRCA1
or BRCA2 are generally identified after full sequencing of both
genes. Therefore the most common clinical question is whether a
variant in BRCA1 or BRCA2 is pathogenic or not. We thus
performed pair wise analyses to determine if BRCAX samples could
be distinguished from those with pathogenic mutations in BRCA1
or BRCA2. Based on observations from hierarchical clustering
analyses and the GPC analysis, we also considered the possibility
that the effect of pathogenic BRCA1/2 mutations (truncating or
missense) affected LCL gene expression. T-tests were performed
using the 20,874 detected probes to elucidate gene differences
between i) BRCA1 or BRCA2 truncating mutations vs BRCAX
without an LCS variant; ii) BRCA1 or BRCA2 missense mutations
vs BRCAX without an LCS variant. The number of genes which
passed these restrictions and the overlap between them is outlined
in Figure 3A and 3C. The comparisons were then repeated with
BRCAX with an LCS variant (Figure 3B and 3D). As expected
when BRCA1 and BRCA2 were compared to BRCAX samples
without an LCS variant, a greater number of genes were deemed
significant compared to BRCA1 or BRCA2 vs BRCAX samples with
an LCS variant.
Support Vector Machines Prediction of BRCA1, BRCA2 and
BRCAX Mutation Status
SVM is a widely accepted classification approach for assessing
differences in mRNA expression, and was used to compare BRCA1
or BRCA2 individually to BRCAX samples. Since our detailed
analysis of gene lists showed that mutation effect (truncating or
missense substitution) appears to affect the genes that are
differentially expressed in the carriers after IR (Figure 3), we
assessed if these gene differences will affect the predictions. We
used SVM with the top 200 genes from the comparison of BRCA1
or BRCA2 truncating mutations to BRCAX, and the top 200 genes
from the comparison of BRCA1 and BRCA2 missense mutations to
BRCAX (Figure 3A and 3C). The genes which differed between
Figure 1. Unsupervised Hierarchical cluster of differences
between BRCAX samples with or without a BRCA1 or BRCA2
sequence variant of Low Clinical Significance. Unsupervised
cluster analysis was performed using 1778 genes that varied in
expression 2-fold from the mean in 10% of BRCAX without a BRCA1/2
LCS variant and BRCAX samples with an LCS. The tree structure at the
top of the cluster shows how related the samples are to each other. The
majority of BRCAX samples without an LCS (black) clustered in a distinct
group away from BRCAX with an LCS variant (red).
doi:10.1371/journal.pgen.1000080.g001
Figure 2. Unsupervised Hierarchical Cluster of Differences between BRCA1, BRCA2 and BRCAX samples. Clustering was based on 4751
genes which varied 2-fold difference in gene expression in at least 10% of samples. There are two main clusters, the BRCAX samples without a BRCA1/
2 LCS variant (black) cluster to the right, whereas BRCA1 (green), BRCA2 (blue) and BRCAX samples with a BRCA1/2 LCS variant (red) are predominantly
located in the left cluster. The missense pathogenic mutations of BRCA1 or BRCA2 are indicated with arrows and 6/9 cluster closest to the BRCAX LCLs.
doi:10.1371/journal.pgen.1000080.g002
Expression Profiles of BRCA1/2 Variants
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in this comparison as too few genes passed the restriction
(Figure 3B and 3D). The top 200 genes are listed in Tables S2,
S3, S4, and S5 and the overlap of the top 200 genes used for
prediction from [BRCA1 (missense) vs BRCAX (noLCS)] and
[BRCA1 (truncating) vs BRCAX (noLCS)] was 16 transcripts, with
no overlap between the top 200 genes from [BRCA2 (missense) vs
BRCAX (noLCS)] and [BRCA2 (truncating) vs BRCAX (noLCS)]. A
total of 715 different genes were represented in the four lists of top
200 gene-lists from comparison of BRCAX (no LCS) to the
different BRCA1/2 groups above. The results are summarised in
Tables 2 and 3. The BRCA2 truncating pathogenic carriers were
consistently predicted with higher accuracy compared to BRCA1
truncating pathogenic carriers. The accuracy of prediction was
improved when the gene list used for prediction was appropriate to
the mutation effect (truncating or missense) being tested. When the
missense-associated gene list was used, pathogenic truncating
mutations were predicted with 35% and 68% accuracy for BRCA1
and BRCA2, respectively. Predictions increased to 71% and 84%
for BRCA1 and BRCA2, respectively, using the truncating-
associated genes. Similarly, the pathogenic missense mutation
carriers were predicted with 83% and 100% accuracy when the
missense-associated gene list is used, but this accuracy was lower or
remained the same when the truncating-specific gene list was used
(83% and 0%). Prediction of BRCAX samples that did not carry an
LCS variant was high in all comparisons (82–94%). In contrast,
prediction of BRCAX samples that did carry an LCS variant was
poor (40–50%).
When using SVM, the significance of the predictions can also be
represented by the distance the prediction is from the plane, where
predictions called with greater confidence are further from the
plane that separates the BRCA1 (or BRCA2) and BRCAX samples.
The significance of the predictions for the BRCA1 pathogenic
missense mutations is summarised in Figure 4. Although both
missense and truncating gene lists correctly predicted 5 of 6
missense mutations, the results show that there is much greater
Table 1. Accuracy of Prediction of Mutation Status using a Gaussian Process Classifier
*
BRCA1 BRCA1 BRCA1 BRCA1
Vs BRCA2 Vs BRCA2 Vs BRCA2 Vs BRCA2
Vs BRCAX (no LCS) Vs BRCAX LCS Vs BRCAX (no LCS) +BRCAX LCS Vs BRCAX (no LCS)
Vs BRCAX LCS
Excluding
pathogenic
missense
62.26% 43.46% 52.36% 53.96%
Including
pathogenic
missense
46.77% 40% 45.83% 47.22%
*2031 genes were used to predict mutation status between groups, as described in the methods section.
doi:10.1371/journal.pgen.1000080.t001
Figure 3. Venn Diagrams of Differences between BRCA1 or BRCA2 and BRCAX LCLs with or without a LCS. T-tests (p-value,0.05) were
performed to determine genes that differed between LCLs as follows: A) BRCA1 Truncating mutations vs BRCAX with no LCS, and BRCA1 missense
mutations vs BRCAX with no LCS; B) BRCA1 Truncating mutations vs BRCAX with an LCS, and BRCA1 missense mutations vs BRCAX with an LCS. C)
BRCA2 Truncating mutations vs BRCAX with no LCS, and BRCA2 missense mutations vs BRCAX with no LCS; D) BRCA2 Truncating mutations vs BRCAX
with an LCS, and BRCA1 missense mutations vs BRCAX with an LCS. For each comparison, the overlap of genes is shown.
doi:10.1371/journal.pgen.1000080.g003
Expression Profiles of BRCA1/2 Variants
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using the missense-derived list.
Pathway Analysis of Genes Associated with Pathogenic
Mutations in BRCA1 or BRCA2
Ingenuity Pathway Analysis of genes which differed between the
LCLs carrying pathogenic truncating or missense mutations of
BRCA1 or BRCA2 compared to BRCAX samples without an LCS
variant was performed to determine the potential functional
relevance of the differentially expressed genes. All BRCA1 and
BRCA2 pathogenic mutations resulted in gene expression changes
relating to cell cycle, cancer and cellular growth and development,
while BRCA1 and BRCA2 missense mutations shared some
additional similarities (cell death and cell development pathways).
There were also alterations in several pathways that were unique
to BRCA1 truncating mutations, BRCA2 truncating mutations,
BRCA1 missense mutations, or BRCA2 missense mutations (Figure
S1).
Discussion
It is difficult to counsel patients with a strong family history of
breast cancer who are found to carry an unclassified variant in
BRCA1 or BRCA2. While management at the level of the family
should remain unchanged from that of a BRCAX family with no
knowledge of a BRCA1/2 mutation, some individuals from high-
risk families may nevertheless interpret information about an
unclassified variant to alter their choices regarding prophylactic
surgery for example, and so require careful counselling. Gene
expression profiling can be used to classify samples based on
phenotype, and its frequent use in laboratories world-wide holds
great promise for clinical application, to the extent that profiling
tools are being developed for diagnostic use e.g. Agendia Inc.
(http://www.agendia.com/).
Expression profiles of short-term fibroblasts have previously
been reported to separate carriers of a heterozygous mutation in
the BRCA1 or BRCA2 genes from sporadic breast-cancer-affected
controls [30,31]. We wished to determine if expression profiling of
LCLs could similarly be used to predict BRCA1 or BRCA2
mutation status, with the ultimate aim of predicting the
significance of unclassified variants of BRCA1 or BRCA2. We
chose LCLs as a minimally invasive source of germline material
that can be maintained as long term cultures, and because
previous studies have shown that LCL array profiling is robust to
sourcing of LCLs established in different laboratories [33]. We
compared expression profiles of irradiated LCLs from BRCA1 and
BRCA2 carriers to those of non-BRCA1/2 BRCAX familial breast
cancer patients, an appropriate reference group for the proposed
evaluation of unclassified variants identified in familial breast
cancer patients. A relatively early time-point of 30 minutes post-
irradiation was chosen to capture gene expression initiation, and
Table 2. Mutation Prediction of BRCA1 and BRCAX samples based on SVM
Gene list used for prediction
* Proportion of mutation group correctly predicted
BRCA1 Truncating BRCA1 Missense BRCAX (no LCS) BRCAX with an LCS
BRCA1 Truncating list 12/17 (71%) 5/6 (83%) 16/17 (94%) 5/10 (50%)
BRCA1 Missense list 6/17 (35%) 5/6 (83%) 14/17 (82%) 4/10 (40%)
*Lists included the 200 Highest Ranked Genes from the comparison of BRCA1 to BRCAX samples without an LCS variant, as described in the methods.
doi:10.1371/journal.pgen.1000080.t002
Table 3. Mutation Prediction of BRCA2 and BRCAX samples based on SVM
Gene list used for prediction
* Proportion of mutation group correctly predicted
BRCA2 Truncating BRCA2 Missense BRCAX (no LCS) BRCAX with an LCS
BRCA2 Truncating list 16/19 (84%) 0/3 (0%) 16/17 (94%) 4/10 (40%)
BRCA2 Missense list 13/19 (68%) 3/3 (100%) 16/17 (94%) 4/10 (40%)
*Lists included the 200 Highest Ranked Genes from the comparison of BRCA2 to BRCAX samples without an LCS variant, as described in the methods.
doi:10.1371/journal.pgen.1000080.t003
Figure 4. Confidence of Predictions for Missense BRCA1 LCLs as
Determined by Distance from the SVM Plane. The SVM plane
separating BRCA1 from BRCAX is shown by the red line. If the sample
falls over the line (black point) the missense mutation is correctly
predicted as pathogenic for BRCA1 mutation. If the sample falls under
the line (red point) the missense mutation is incorrectly predicted as
BRCAX. The gene lists used for the predictions are the top 200 genes
from BRCA1 missense vs BRCAX, and the top 200 genes from BRCA1
Truncating vs BRCAX.
doi:10.1371/journal.pgen.1000080.g004
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previously been shown that 10Gy IR treatment of normal LCLs
has an effect on the transcriptional response, with greatest change
in mRNA levels for most genes within one hour post-treatment
[35], and studies of mouse brain gene expression after whole-body
low-dose irradiation have shown that a large number of early IR
response genes can be measured at the 30 minute time point [36].
A number of BRCAX cases carried BRCA1 or BRCA2 sequence
variants that had been previously classified using multifactorial
likelihood modelling methods to be neutral or of low clinical
significance-that is, these rare variants are extremely unlikely to be
a high-risk mutation in either of these genes, but the modelling
methods used cannot assess whether they are truly neutral or
associated with a much lower risk of disease. We found that the
BRCAX samples with such LCS variants were separated from the
majority of BRCAX samples without such LCS variants using
unsupervised hierarchical clustering. This result indicates that
LCS samples differ in expression profile as a result of their BRCA1
or BRCA2 sequence variant, and was substantiated by the class
prediction methods: GPC prediction of the BRCAX samples
decreased in accuracy when BRCAX samples with an LCS were
included. In addition, SVM to detect BRCA1 or BRCA2 mutation-
related gene lists yielded differences in the significant genes for
comparisons to BRCAX samples without an LCS variant,
compared to BRCAX samples with an LCS variant. Accordingly,
prediction of BRCAX subgroup status based on the more robust
gene list derived from comparisons to BRCAX individuals without
an LCS variant was generally poorer for BRCAX samples with an
LCS (40–50%) compared to those without an LCS (82%–94%).
These rather provocative results indicate that the possible effect of
all rare variants should be considered in development of assays to
assess which variants have features of high-risk mutations.
Moreover, the similarity in expression profile of these variants to
other BRCA1/2 pathogenic mutations suggests that at least some
of these LCS variants may confer small-moderate risks of breast
cancer, presumably acting in concert with alterations in other
genes in the BRCA1/2 pathway to lead to breast cancer. Given the
rarity of these variants, alternative statistical approaches will be
required to assess the risk of cancer associated with them.
The assay conditions used in this study could not distinguish
between samples with pathogenic BRCA1 mutations and those
with pathogenic BRCA2 mutations. Ionising radiation has
previously been show to separate fibroblast cells which carry
BRCA1 or BRCA2 mutations from sporadic cases with 100%
accuracy [31], but our experiment differs in several respects. We
compared BRCA1 and BRCA2 cases to familial BRCAX cases as an
appropriate reference group for familial breast cases likely to be
identified as carriers of BRCA1/2 mutations or unclassified
variants, we used LCLs instead of fibroblasts, we selected a lower
IR exposure (10Gy vs 15Gy), and we chose a relatively early time
point of 30 mins after exposure to IR in order to gain a better
understanding of the functional differences in response to IR
between the BRCA1, BRCA2 and BRCAX cell lines. Some or all of
these factors may explain the difference in the ability of this study
to distinguish BRCA1 from BRCA2, both of which are involved in
DNA damage repair. However, differences in post-irradiation
response between BRCAX individuals and BRCA1/2 mutation
carriers are supported by alternative analysis we have conducted of
the subset of genes reported to be involved in post-irradiation
response, comparing mutation-negative normal female controls to
BRCAX individuals without an LCS variant, or to BRCA1 or
BRCA2 truncating mutation carriers. Our results indicate
substantial differences in radiation response between normal
controls and the patient groups, and also considerable differences
between the BRCAX group and BRCA1 and BRCA2 carriers [37].
Alternative IR exposures and/or post-IR timepoints, and possibly
different DNA damaging agents, should be considered for future
experiments.
The ultimate aim of this experiment was to identify array
profiles that would be useful for the classification of unclassified
sequence variants of BRCA1 or BRCA2. In the clinical setting,
individuals generally present with full sequencing of both genes,
and presence of a variant in one gene or the other. We thus
assessed the ability to distinguish BRCA1 or BRCA2, separately,
from BRCAX individuals. Importantly, since most unclassified
variants are predicted to cause amino acid substitutions, we also
assessed the relevance of mutation effect for expression profiles.
We found that the genes which significantly differed between
BRCA1 or BRCA2 and BRCAX LCLs were dependent on mutation
effect. Accordingly, the SVM prediction for each mutation effect
was best if the appropriate gene list was used, in terms of both
accuracy of prediction (BRCA1 or BRCA2 vs BRCAX) and
confidence in the classification as determined by the distance of
the prediction from the SVM plane. Thus we strongly urge that
mutation effect is taken into account if this type of assay is to be
developed for use in predicting the clinical significance of BRCA1/
2 variants. The current challenge is that few missense variants
have been classified with respect to their clinical significance, with
the only 23 individual missense variants termed clinically
important by BIC, 17 in BRCA1 and six in BRCA2. Moreover,
these are restricted in terms of the domains/regions in which they
occur, residing in the BRCA1 start site (n=2), ring finger (n=4) or
transactivation domains (n=11), and the BRCA2 CDK2
phosphorylation site (n=3) or at one codon (2336, n=3) in a
region of unknown function. It will thus be difficult to accrue a
panel of known pathogenic missense variants for use in such
predictive assays, and will require a concerted collaborative effort.
Assuming sufficient pathogenic variants are identified, the
successful execution of such a study may eventually distinguish
missense-associated gene expression patterns that are generic to
missense mutations, and/or those that are specific to the domain
location of missense mutations. In addition, a possibly greater
challenge will be identifying assay conditions (cell type, perturba-
tion, time-point etc) that can also identify gene expression
differences between patients with rare variants of low clinical
significance in BRCA1 and/or BRCA2 and those with truly high-
risk pathogenic mutations (truncating or missense) in these genes.
Our study, using conditions that were not optimal for separating
BRCA1 and BRCA2 mutations nevertheless identified gene
expression differences between BRCA1/2 pathogenic mutations
and LCS variants, suggesting that larger sample sizes and further
experimentation may identify a more robust gene list to separate
pathogenic mutations, variants of low clinical significance, and
individuals with no sequence alterations in BRCA1/2.
Pathway analysis confirming altered expression of cancer, cell
proliferation and cell cycle pathways in BRCA1 and BRCA2
mutation carrier groups is consistent with the known functions of
BRCA1 and BRCA2 [38,39]. The pathway differences by mutation
type such as cell death and development may reflect that the
majority of truncating mutations result in activation of the
nonsense mediated decay pathway [40] and complete loss of
protein, whereas most missense mutations are likely to result in
more subtle effects through ablation of individual functional
domains. Some pathways identified were unexpected and are only
present in a single mutation type, and it is thus likely that at least
some of these pathways were generated by chance alone.
In conclusion, we have provided evidence that carriers of
BRCA1 and BRCA2 variants considered to be of low clinical
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familial cases, but resembling profiles of pathogenic BRCA1/2
cases, indicating that further work will be required to evaluate
their possible association with a low-moderate risk of cancer. We
have also shown that it will be important to consider mutation
effect when developing array-based assays for predicting the
clinical significance of BRCA1 or BRCA2 unclassified variants.
Lastly, our findings demonstrate the ability of array profiling of
immortalized lines derived from lymphoblastoid cells to detect
germline mutations in genes that result in breast and ovarian
cancer, and thus have relevance to the investigation of other
genetic diseases irrespective of the organs or tissues they affect.
Materials and Methods
Subjects and Lymphoblastoid Cell Lines
LCLs were derived from breast cancer-affected women
recruited into the Kathleen Cuningham Foundation for Research
into Breast Cancer (kConFab), a consortium which ascertains
multiple-case breast cancer families [41]. These include families in
which one or more carriers of a BRCA1 or BRCA2 mutation have
been identified, and families in which no predisposing mutation
has been identified (BRCAX). The recruitment criteria for BRCAX
families are: 1) at least one member of the family at high-risk
according to the National Breast Cancer Centre Category III
guidelines (http://www.nbcc.org.au), and four or more cases of
breast or ovarian cancer (on one side of the family), and two or
more living affecteds with breast or ovarian cancer, and four or
more living first or second degree unaffected female relatives of
affected cases, over the age of 18 ; 2) two or three cases of breast or
ovarian cancer (on one side of the family) in same or adjacent
generations, if at least one of these cases is ‘high risk’ (i.e. male
breast cancer, bilateral breast cancer, breast plus ovarian cancer in
the same individual, or breast cancer with onset less than
40 years), and two or more living affected cases with breast or
ovarian cancer, and four or more living first or second degree
unaffected female relatives of affected cases, over the age of 18.
Classifications for BRCA1 and BRCA2 pathogenic mutations
and variants of low clinical significance (LCS) are described
on http://www.kconfab.org/Progress/Classification.shtml. Briefly,
LCS variants include BRCA1 or BRCA2 variants described in trans
with a deleterious mutation in the same gene in an individual and
occur at a frequency of less than 1% in unaffected controls, or
considered neutral/low clinical significance as measured using
multifactorial likelihood approaches [16,19,21,22].
A cohort of 72 LCLs were used in this study. The full listing of
mutation details for LCLs is shown in Table S1. In brief, the study
included:
(a) 23 LCLs from women carrying a pathogenic mutation in
BRCA1, 17 of which are predicted to lead to a truncated
protein, and six of which were missense mutations (26300
T.G C61G; 26 5242 C.A A1708E; 16 5331 G.A
G1738R; 165632 T.A V1838E);
(b) 22 LCLs from women carrying a pathogenic mutation in
BRCA2, 19 of which are predicted to lead to a truncated
protein, and three of which were missense mutations (36
8395 G.C D2723H, one of which also carried the LCS
variant 9079 G.A A2951T);
(c) 27 LCLs from women from breast cancer families that have
tested negative for pathogenic mutations in BRCA1 or
BRCA2 (BRCAX) after complete sequencing and multiplex
ligation-dependent probe amplification gene dosage assay
(MLPA) large deletion testing of BRCA1 and BRCA2. Ten
samples, carried either BRCA1 or BRCA2 sequence germline
variants considered from multifactorial likelihood classifica-
tion to be LCS (BRCA1 3582 G.C D1155H, 1605 C.T
R496C, 5236 G.C G1706A (2 samples); BRCA2 353 A.G
Y42C, 2834 C.T S869L, 3031 G.A D935N (3 samples),
8795 A.C E2856A) [16,19,21,22](unpublished data). The
remaining 17 samples carried no BRCA1 or BRCA2 sequence
variants other than common polymorphisms.
Gene Expression Profiling
LCLs were grown in RPMI 1640 media with 15% fetal bovine
serum, 1% penicillin-streptomycin and 1% L-glutamine. The cell
number was normalised and fresh medium was added to cells 24hr
prior to irradiation with 10Gy, using a calibrated Cs137 c-source
delivering 1 Gy/1.5 min. Total RNA was harvested 30min later
using an RNeasy kit (Qiagen, Doncaster, VIC). The Illumina
Totalprep RNA amplification kit (Ambion, Austin, TX) was used
to amplify and biotinylate 450ng of total RNA. Biotinylated RNA
was hybridised overnight at 55uC to Illumina Human-6 version 1
BeadChips containing .46,000 probes (Illumina Inc., San Diego,
CA). The microarrays were washed, stained with streptavidin-Cy3,
and then scanned with an Illumina BeadArray Scanner. Duplicate
arrays were performed for eight cell lines across the different
groups for quality control purposes, with duplicates performed on
different days. All duplicate arrays showed highest correlation with
each other (correlation .0.98). Duplicate samples were not
included in analysis. Comparative real-time PCR was performed
for ten genes on 6–8 samples, using GAPDH to normalise all data,
and the comparative cycle threshold method for analysis. Paired
student t tests were performed to determine the significance of
gene expression changes. Expression differences were validated for
8/10 genes tested.
Data Analysis
Raw data was imported into Illumina Beadstudio and then
exported into Genespring v7.3 (Agilent Technologies, Forest Hill,
VIC) for further analysis. Data was normalised (per chip
normalized to 50th percentile and per gene normalized to median)
and filtered using an Illumina detection score of .0.99 in at least
one sample, which yielded 20,874 probes that were used in all
further analyses. The majority of these probes used in the analysis
were designed by Illumina to assay the curated portion of the NIH
Ref sequence database-16,923 were present in the Ref sequence
database, comprising 65% of all Ref sequence-listed probes on the
array. Transcripts which had a .2-fold change versus the mean
were visualised using unsupervised Hierarchical Clustering
(Figures 1 and 2). The clustering method used was a Pearson
correlation similarity measure with an average linkage clustering
algorithm. Two different methods were used to classify LCLs
based on mutation status: (1) A multi comparison Gaussian Process
Classifier (GPC) [42] with Leave-One-Out cross-validation to
determine the prediction errors, as previously used to predict
BRCA1/BRCA2 mutation status of irradiated fibroblasts [31]; (2) A
linear classification method commonly used for classification of
microarray data, Support Vector Machines (SVM) [43] with
Leave-One-Out cross validation. The GPC analysis used 2031
genes which were derived from a t-test to select the genes that were
significantly over/under-expressed at the 5% significance, while
the SVM used genes from the 20,874 detected probes which
differed between groups of LCLs using a t-test p of 0.05. All
resulting gene lists are available as supplementary data and all data
is available via GEO: Accession number GSE10905.
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com) was used for biological interpretation of gene lists. Analysis of
the transcripts found to be up- and down-regulated in irradiated
LCLs as identified for the different mutation categories identified
those biochemical networks most likely to be affected by a BRCA1
and BRCA2 truncating and missense mutation, relative to BRCAX.
Those pathways with multiple hits or a significance score $20 were
then compared.
Supporting Information
Figure S1 Biological Pathways defined by genes dysregulated in
BRCA1 and BRCA2 mutation carriers. Pathways identified by
Ingenuity pathway analysis of the top 200 genes defined for
truncating and missense BRCA1 or BRCA2 mutations compared to
BRCAX without an LCS were compared for overlap. Bold lines
and pathways denoted in uppercase indicate biological pathways
identified as differentially expressed in both BRCA1 and BRCA2
Found at: doi:10.1371/journal.pgen.1000080.s001 (0.20 MB TIF)
Table S1 Detailed Mutation Status of LCLs.
Found at: doi:10.1371/journal.pgen.1000080.s002 (0.03 MB
XLS)
Table S2 The top 200 significant genes from the comparison of
BRCA1 Missense vs BRCAX without an LCS.
Found at: doi:10.1371/journal.pgen.1000080.s003 (0.05 MB
XLS)
Table S3 The top 200 significant genes from the comparison of
BRCA1 Truncating vs BRCAX without an LCS.
Found at: doi:10.1371/journal.pgen.1000080.s004 (0.05 MB
XLS)
Table S4 The top 200 significant genes from the comparison of
BRCA2 Missense vs BRCAX without an LCS.
Found at: doi:10.1371/journal.pgen.1000080.s005 (0.06 MB
XLS)
Table S5 The top 200 significant genes from the comparison of
BRCA2 Truncating vs BRCAX without an LCS.
Found at: doi:10.1371/journal.pgen.1000080.s006 (0.05 MB
XLS)
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